Alternative Mechanisms of Multidrug Resistance in Cancer:
Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed t...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Birkhäuser Boston
1995
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and interest. No doubt, multidrug resistance is a "fashionable" topic, but there are many fashions displayed on the cat-walk of scientific literature. One can rationalize that the forces driving our concern with multi drug resistance reflect the frustration of pharmaceutical companies and oncologists alike: as soon as a new anticancer drug enters clinical trials, cancer cells start eluding extinction with their elaborate and successful mechanisms. Many grants have been awarded and spent, only to confirm the futility of our efforts to defeat this cellular Darwinism. Our medical and scientific training makes it hard, if not impossible, to accept that the survival of a malignant cell, alone or as part of a tissue, is part of the continuance of life. Since exposure to noxious and lethal substances is unavoidable, cells have been forced to develop a multitude of mechanisms to prevent entry or accelerate exit of such materials from intracellular space |
| Beschreibung: | 1 Online-Ressource (281 p) |
| ISBN: | 9781461598527 |
| DOI: | 10.1007/978-1-4615-9852-7 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046143801 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1995 |||| o||u| ||||||eng d | ||
| 020 | |a 9781461598527 |9 978-1-4615-9852-7 | ||
| 024 | 7 | |a 10.1007/978-1-4615-9852-7 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-9852-7 | ||
| 035 | |a (OCoLC)1118989808 | ||
| 035 | |a (DE-599)BVBBV046143801 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a WE 5300 |0 (DE-625)148304: |2 rvk | ||
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Alternative Mechanisms of Multidrug Resistance in Cancer |c edited by John A. Kellen |
| 264 | 1 | |a Boston, MA |b Birkhäuser Boston |c 1995 | |
| 300 | |a 1 Online-Ressource (281 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and interest. No doubt, multidrug resistance is a "fashionable" topic, but there are many fashions displayed on the cat-walk of scientific literature. One can rationalize that the forces driving our concern with multi drug resistance reflect the frustration of pharmaceutical companies and oncologists alike: as soon as a new anticancer drug enters clinical trials, cancer cells start eluding extinction with their elaborate and successful mechanisms. Many grants have been awarded and spent, only to confirm the futility of our efforts to defeat this cellular Darwinism. Our medical and scientific training makes it hard, if not impossible, to accept that the survival of a malignant cell, alone or as part of a tissue, is part of the continuance of life. Since exposure to noxious and lethal substances is unavoidable, cells have been forced to develop a multitude of mechanisms to prevent entry or accelerate exit of such materials from intracellular space | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a Drug Resistance | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Drug interactions | |
| 650 | 0 | 7 | |a Multidrug-Resistenz |0 (DE-588)4315848-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Multidrug-Resistenz |0 (DE-588)4315848-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Kellen, John A. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461598541 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780817637750 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461598534 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-9852-7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031523984 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4615-9852-7 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180478358454272 |
|---|---|
| any_adam_object | |
| author2 | Kellen, John A. |
| author2_role | edt |
| author2_variant | j a k ja jak |
| author_facet | Kellen, John A. |
| building | Verbundindex |
| bvnumber | BV046143801 |
| classification_rvk | WE 5300 XI 7000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-9852-7 (OCoLC)1118989808 (DE-599)BVBBV046143801 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Biologie Medizin |
| doi_str_mv | 10.1007/978-1-4615-9852-7 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03485nmm a2200577zc 4500</leader><controlfield tag="001">BV046143801</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1995 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461598527</subfield><subfield code="9">978-1-4615-9852-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-9852-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-9852-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118989808</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046143801</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WE 5300</subfield><subfield code="0">(DE-625)148304:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Alternative Mechanisms of Multidrug Resistance in Cancer</subfield><subfield code="c">edited by John A. Kellen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Birkhäuser Boston</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (281 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and interest. No doubt, multidrug resistance is a "fashionable" topic, but there are many fashions displayed on the cat-walk of scientific literature. One can rationalize that the forces driving our concern with multi drug resistance reflect the frustration of pharmaceutical companies and oncologists alike: as soon as a new anticancer drug enters clinical trials, cancer cells start eluding extinction with their elaborate and successful mechanisms. Many grants have been awarded and spent, only to confirm the futility of our efforts to defeat this cellular Darwinism. Our medical and scientific training makes it hard, if not impossible, to accept that the survival of a malignant cell, alone or as part of a tissue, is part of the continuance of life. Since exposure to noxious and lethal substances is unavoidable, cells have been forced to develop a multitude of mechanisms to prevent entry or accelerate exit of such materials from intracellular space</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug interactions</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Multidrug-Resistenz</subfield><subfield code="0">(DE-588)4315848-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Multidrug-Resistenz</subfield><subfield code="0">(DE-588)4315848-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kellen, John A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461598541</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780817637750</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461598534</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-9852-7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031523984</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-9852-7</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046143801 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:24Z |
| institution | BVB |
| isbn | 9781461598527 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031523984 |
| oclc_num | 1118989808 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (281 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | Birkhäuser Boston |
| record_format | marc |
| spelling | Alternative Mechanisms of Multidrug Resistance in Cancer edited by John A. Kellen Boston, MA Birkhäuser Boston 1995 1 Online-Ressource (281 p) txt rdacontent c rdamedia cr rdacarrier Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and interest. No doubt, multidrug resistance is a "fashionable" topic, but there are many fashions displayed on the cat-walk of scientific literature. One can rationalize that the forces driving our concern with multi drug resistance reflect the frustration of pharmaceutical companies and oncologists alike: as soon as a new anticancer drug enters clinical trials, cancer cells start eluding extinction with their elaborate and successful mechanisms. Many grants have been awarded and spent, only to confirm the futility of our efforts to defeat this cellular Darwinism. Our medical and scientific training makes it hard, if not impossible, to accept that the survival of a malignant cell, alone or as part of a tissue, is part of the continuance of life. Since exposure to noxious and lethal substances is unavoidable, cells have been forced to develop a multitude of mechanisms to prevent entry or accelerate exit of such materials from intracellular space Oncology Pharmacology/Toxicology Cancer Research Drug Resistance Oncology Toxicology Drug interactions Multidrug-Resistenz (DE-588)4315848-1 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Multidrug-Resistenz (DE-588)4315848-1 s DE-604 Kellen, John A. edt Erscheint auch als Druck-Ausgabe 9781461598541 Erscheint auch als Druck-Ausgabe 9780817637750 Erscheint auch als Druck-Ausgabe 9781461598534 https://doi.org/10.1007/978-1-4615-9852-7 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Alternative Mechanisms of Multidrug Resistance in Cancer Oncology Pharmacology/Toxicology Cancer Research Drug Resistance Oncology Toxicology Drug interactions Multidrug-Resistenz (DE-588)4315848-1 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4315848-1 (DE-588)4073781-0 (DE-588)4143413-4 |
| title | Alternative Mechanisms of Multidrug Resistance in Cancer |
| title_auth | Alternative Mechanisms of Multidrug Resistance in Cancer |
| title_exact_search | Alternative Mechanisms of Multidrug Resistance in Cancer |
| title_full | Alternative Mechanisms of Multidrug Resistance in Cancer edited by John A. Kellen |
| title_fullStr | Alternative Mechanisms of Multidrug Resistance in Cancer edited by John A. Kellen |
| title_full_unstemmed | Alternative Mechanisms of Multidrug Resistance in Cancer edited by John A. Kellen |
| title_short | Alternative Mechanisms of Multidrug Resistance in Cancer |
| title_sort | alternative mechanisms of multidrug resistance in cancer |
| topic | Oncology Pharmacology/Toxicology Cancer Research Drug Resistance Oncology Toxicology Drug interactions Multidrug-Resistenz (DE-588)4315848-1 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Oncology Pharmacology/Toxicology Cancer Research Drug Resistance Oncology Toxicology Drug interactions Multidrug-Resistenz Krebs Medizin Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4615-9852-7 |
| work_keys_str_mv | AT kellenjohna alternativemechanismsofmultidrugresistanceincancer |